Skip to content

Author

M. Borad

We have 5 of 602 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

HER2/ERBB2 and Genomic Alterations in Patients with Gallbladder Cancer from Argentina

Background/Objectives: Gallbladder cancer (GBC) is highly prevalent in Western Argentina, where the frequency and clinical significance of HER2/ERBB2 abnormalities remain unknown. We investigated the prevalence, prognostic impact, and genomic co-occurrence of HER2/ERBB2 alterations in Argentine patients with GBC. Metho...

G. F. Arroyo, Gabriela Acosta Haab, Aylén Avila et al. · 0 citations
Sep 2026

Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma With Persistent Lymphovascular Invasion or Lymph Node Involvement After Neoadjuvant Chemotherapy.

LVI and LN involvement were independently associated with worse OS and the use of AT in patients with persistent LVI and LN involvement was not associated with improved OS after NAT.

Valerie L. Armstrong, Yu-Hui H. Chang, C. Stucky et al. · 0 citations
Review Open access Oct 2026

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.

BACKGROUND AIMS To evaluate safety and efficacy of FGFR1-3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements (FGFR2F), mutations (FGFR2M), or amplifications (FGFR2A), previously treated with chemotherapy. APPROACH RESULTS Open-label, non-contro...

M. Borad, Michele Droz Dit Busset, M. Javle et al. · 0 citations
#data science Review Open access Oct 2026

Biweekly gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a systematic review

Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the standard GA schedule (days 1, 8, and 15 of a 28-day cycle)...

C. Hoyek, C. Eslinger, Angelo Pirozzi et al. · 0 citations
Open access Aug 2026

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC, an unmet need after first-line immunotherapy.

Nguyen H. Tran, M. Palmer, Angela Ulrich et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.